Table 2.
Patient characteristics and cumulative doses of chemotherapy agents
| Sex (n) & Age | Immunophenotypes type of ALL (n) | BMA (%) at the end of induction | Prognostic group (n) | NCI risk groups (n) | Vincristine dose (%) | Daunorubicin dose (%) | L-asparginase dose (%) | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| M | F | M/F | MA.DX | PB | EPB | TC | POB | CR | Hy | PR | FV | LFV | LR | HR | VHR | L | I | H | SD | H | SD | H | |
| Case group | 17 | 6 | 2.8 | 5.1 ± 0.9 | 13 | 6 | 2 | 2 | 50 | 35.7 | 14.3 | 9 | 6 | 9 | 5 | 1 | 57.1 | 14.3 | 28.6 | 75 | 25 | 84.6 | 15.4 |
| Control group | 5 | 11 | 0.04 | 7.3 ± 1.0 | 8 | 7 | 1 | - | 76.9 | 23.1 | - | 6 | 1 | 12 | 4 | - | 13.3 | 26.7 | 60 | 90 | 10 | 15.4 | 73.3 |
Abbreviations: n, number; BMA, Bone Marrow Aspiration; NCI, National Cancer Institute; M, Male; F, Female; M/F, Male to Female; MA.DX, Mean Age at Diagnosis; PB, Pre-B; EPB, Early Pre-B; TC, T-Cell; POB, Pro-B; CR, Complete Remission; Hy, Hypocellular; PR, Partial Remission; FV, Favorable; LFV, Less Favorable; LR, Low Risk; HR, High Risk; VHR, Very High Risk; L, Low; I, Intermediate; H, High; SD, Standard